Specific inhibition of basal mitogen-activated protein kinases and phosphatidylinositol 3 kinase activities in leukemia cells: a possible therapeutic role for the kinase inhibitors

Experimental Hematology

Volumn 36, Issue 1, 2008, Pages 28-36

  Champelovier, Pierre ^a   El Atifi, Michèle ^b   Pautre, Virginie ^b   Rostaing, Béatrice ^b   Berger, François ^b   Seigneurin, Daniel ^a  

^a PSL RESEARCH UNIVERSITY   (France)

^b UNIV GRENOBLE ALPES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CD11 ANTIGEN; CD15 ANTIGEN; CD18 ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN P21; STRESS ACTIVATED PROTEIN KINASE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE G2 PHASE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; GENE INACTIVATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MESSENGER RNA SYNTHESIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THERAPY EFFECT;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTHRACENES; APOPTOSIS; CELL CYCLE; CELL CYCLE PROTEINS; CELL DIFFERENTIATION; CELL DIVISION; CELL LINE, TUMOR; CHROMONES; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; FLAVONOIDS; GENE EXPRESSION REGULATION, LEUKEMIC; HL-60 CELLS; HUMANS; IMIDAZOLES; LEUKEMIA; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASES; MONOCYTES; MORPHOLINES; NEOPLASM PROTEINS; PROTEIN KINASE INHIBITORS; PYRIDINES; U937 CELLS;

EID: 37249084066     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2007.08.027     Document Type: Article

References (41)

1. Yang S.-H., Sharrocks A.D., and Whitmarsh A.J. Transcriptional regulation by the MAP kinase signaling cascades. Gene 320 (2003) 3-21
2. Dangi S., Cha H., and Shapiro P. Requirement for phosphatidylinositol-3 kinase activity during progression through S-phase and entry into mitosis. Cell Signal 15 (2003) 667-675
3. Liu X., Yan S., Zhou T., Terada Y., and Erikson R.L. The MAP kinase pathway is required for entry into mitosis and cell survival. Oncogene 23 (2004) 763-776
4. Johnson G.L., and Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 298 (2002) 1911-1912
5. Xia Z., Dickens M., Raingeaud J., Davis R.J., and Greenberg M.E. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270 (1995) 1326-1331
6. Davies S.P., Reddy H., Caivano M., and Cohen P. Specificity and mechanisms of action of some commonly used protein kinase inhibitors. Biochem J 351 (2000) 95-105
7. Champelovier P., Seigneurin D., Leroux D., Micouin C., and Kolodie L. Establishment and characterisation of a granulocytic subclone (UM384) from the monoblastic cell line U937. Exp Hematol 17 (1989) 779-784
8. Champelovier P., Pautre V., El Atifi M., et al. Resistance to phorbol ester-induced differentiation in human myeloid leukemia cells: a hypothetic role for the mRNA stabilization process. Leukemia Res 30 (2006) 1407-1416
9. Eisen M.B., and Brown P.O. DNA arrays for analysis of gene expression. Methods Enzymol 303 (1999) 179-205
10. Collins S.J., Ruscetti F.W., Gallagher R.E., and Gallo R.C. Terminal differentiation of human promyelocytic leukemia cells induced by dimethyl sulfoxide and other polar compounds. Proc Natl Acad Sci U S A 75 (1978) 2458-2462
11. Georgakis G.V., Li Y., Rasssdakis G.Z., et al. Inhibition of the phosphatidylinositol-3 kinase/Akt promotes G1 cell cycle arrest and apoptosis in Hodgkin lymphoma. Br J Haematol 132 (2006) 503-511
12. Moon D.-O., Park C., Heo M.-S., et al. PD98059 triggers G1 arrest and apoptosis in human leukemic U937 cells through downregulation of Akt signal pathway. Int Immunopharmacol 7 (2007) 36-45
13. Usui T., Yoshida M., Abe K., Osada H., Isono K., and Beppu T. Uncoupled cell cycle without mitosis induced by a protein kinase inhibitor, K-252a. J Cell Biol 115 (1991) 1275-1282
14. Chang B.-D., Broude E.V., Fang J., et al. p21waf1/cip1/sdi1-induced growth arrest is associated with depletion of mitosis-control proteins and leads to abnormal mitosis and endoreplication in recovering cells. Oncogene 19 (2000) 2165-2170
15. Vitrat N., Chen-Solal K., Pique C., et al. Endomitosis of human megakaryocytes are due to abortive mitosis. Blood 91 (1998) 3711-3723
16. Reiterer G., and Yen A. Inhibition of the Janus Kinase family increases extracellular signal-regulated kinase 1/2 phosphorylation and causes endoreplication. Cancer Res 66 (2006) 9083-9089
17. Nakata S., Kawano T., Saito-Akita S., et al. MEK and p38MAPK inhibitors potentiate TNF-alpha induced apoptosis in U937 cells. Anticancer Res 21 (2001) 167-171
18. Yu C., Mao X., and Li W.X. Inhibition of the PI3K pathway sensitizes fludarabine-induced apoptosis in human leukemic cells through an inactivation of MAPK-dependent pathway. Biochem Biophys Res Commun 331 (2005) 391-397
19. Milella M., Precupanu C.M., Gregorj C., et al. Beyond single pathway inhibition: MEK inhibitors as a platform for the development of pharmacological combinations with synergistic anti-leukemic effects. Curr Pharm Des 11 (2005) 2779-2795
20. Yu C., Krystal G., Varticovski R., et al. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitor interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells. Cancer Res 62 (2002) 188-199
21. Nguyen T.K., Rahmani M., Harada H., Dent P., and Grant S. MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the duel Abl/Src inhibitor BMS-354-825. Blood 109 (2007) 4006-4015
22. Barancik M., Bohacova V., Sedlack J., Sulova Z., and Breier A. LY294002, a specific inhibitor of PI3K/Akt kinase pathway, antagonizes P-glycoprotein-mediated multidrug resistance. Eur J Pharm Sci 29 (2006) 426-434
23. Tazzari P.L., Cappellini A., Ricci F., et al. Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts. Leukemia 21 (2007) 427-438
24. Tabellini G., Cappellini A., Tazzari P.L., et al. Phosphoinisitide 3-kinase/Akt involvement in arsenic trioxide resistance of human leukemia cells. J Cell Physiol 202 (2005) 623-634
25. Schwarzinger I., Valent P., Koller U., et al. Prognostic significance of surface marker expression on blasts of patients with de novo acute myeloblastic leukemia. J Clin Oncol 8 (1990) 423-430
26. Repp R., Schaekel U., Helm G., et al. AML-SHG Study Group. Immunophenotyping is an independent factor for risk stratification in AML. Cytometry B Clin Cytom 53 (2003) 11-19
27. Bradstock K., Matthews J., Benson E., Page F., Bishop J., and the Australian Leukemia Study Group. Prognostic value of immunophenotyping in acute myeloid leukemia. Blood 84 (1994) 1220-1225
28. Brouwer R.E., Hoefnagel J., van der Burg B., et al. Expression of co-stimulatory and adhesion molecules and chemokine or apoptosis receptors on acute myeloid leukemia: high CD40 and CD11a expression correlates with poor prognosis. Br J Haematol 115 (2001) 298-308
29. Graf M., Reif S., Hecht K., et al. High expression of costimulatory molecules correlates with low relapse-free survival probability in acute myeloid leukemia (AML). Ann Hematol 84 (2005) 287-297
30. Baines P., Fisher J., Truran L., et al. The MEK inhibitor, PD98059, reduces survival but does not block acute myeloid leukemia blast maturation in vitro. Eur J Haematol 64 (2000) 211-218
31. Yang G.S., Minden M.D., and McCulloch E.A. Regulation by retinoic acid and hydrocortisone of the anthracycline sensitivity of blast cells of acute myeloid leukemia. Leukemia 8 (1994) 2065-2075
32. Bradbury D.A., Aldington S., Zhu Y.-M., and Russel N.H. Down-regulation of bcl-2 in AML blasts by all-trans retinoic acid and its relationship to CD34 antigen expression. Br J Hematol 94 (1996) 671-675
33. Sato S., Tomoyasu S., Okabe-Kado J., et al. Induction of differentiation and enhancement of vincristine sensitivity of human erythroleukemia HEL cells by vesnarinone, a positive inotropic agent. Exp Hematol 24 (1996) 37-42
34. Amran D., Sancho P., Fernandez, et al. Pharmacological inhibitors of extracellular signal-regulated protein kinases attenuate the apoptotic action of cisplatin in human myeloid leukemia via glutathione-independent reduction in intracellular drug accumulation. Biochim Biophys Acta 1743 (2005) 269-279
35. Ricciardi M.R., McQueen T., Chism D., et al. Quantitative single cell determination of ERK phosphorylation and regulation in relapsed and refractory primary acute myeloid leukemia. Leukemia 19 (2005) 1543-1549
36. Morgan M.A., Dolp O., and Reuter C.W.M. Cell-cycle-dependent activation of mitogen-activated protein kinase kinase (MEK-1/2) in myeloid leukemia cell lines and induction of growth inhibition and apoptosis by inhibitors of RAS signaling. Blood 97 (2001) 1823-1834
37. Bonati A., Lunghi P., Gammaitoni L., et al. MEK-ERK pathway is expressed but not activated in high proliferating, self-renewing cord blood hematopoietic progenitors. Hematol J 3 (2002) 105-113
38. Dent P., and Grant S. Pharmacologic interruption of the mitogen-activated extracellular regulated kinase/mitogen-activated protein kinase signal transduction pathway: potential role in promoting cytotoxic drug action. Clin Cancer Res 7 (2001) 775-783
39. Lunghi P., Tabilio A., Dall'Aglio P.P., et al. Downmodulation of ERK activity inhibits the proliferation and induces the apoptosis of primary acute myelogenous leukemia blasts. Leukemia 17 (2003) 1783-1793
40. Wu J., Wong W.W.-L., Khosravi F., Minden M.D., and Penn L.Z. Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to Lovastin-induced apoptosis. Cancer Res 64 (2004) 6461-6468
41. Milella M., Kornblau S.M., Estrov Z., et al. Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J Clin Invest 108 (2001) 851-859